Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
- CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility. Studies conducted in the neoadjuvant setting might help to explain the discordant results.
Author: | Sibylle LoiblORCiDGND, Jenny FurlanettoORCiDGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-784237 |
DOI: | https://doi.org/10.1016/j.breast.2021.12.008 |
ISSN: | 0960-9776 |
Parent Title (English): | The Breast |
Publisher: | Elsevier |
Place of publication: | Amsterdam |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2022/04/25 |
Year of first Publication: | 2021 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Contributing Corporation: | International Breast Cancer Conference (17, 2021, Sankt Gallen) |
Release Date: | 2023/10/12 |
Tag: | CDK4/6 inhibitors; Early setting; Endocrine therapy; Hormone receptor positive breast cancer |
Volume: | 620.2022 |
Page Number: | 10 |
First Page: | S70 |
Last Page: | S79 |
HeBIS-PPN: | 517174022 |
Institutes: | Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |